-$0.08 EPS Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter
Equities research analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to announce ($0.08) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Ionis Pharmaceuticals’ earnings, with estimates ranging from ($0.50) to $0.29. Ionis Pharmaceuticals reported earnings of $0.21 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 138.1%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full-year earnings of ($0.14) per share for the current fiscal year, with EPS estimates ranging from ($0.57) to $0.22. For the next financial year, analysts anticipate that the business will report earnings of $0.35 per share, with EPS estimates ranging from ($1.10) to $2.91. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ionis Pharmaceuticals.
Several equities research analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price objective on the stock in a research report on Tuesday, October 17th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. BMO Capital Markets boosted their price objective on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Finally, Morgan Stanley boosted their price objective on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $50.76.
In other Ionis Pharmaceuticals news, Director B Lynne Parshall sold 5,986 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $51.76, for a total value of $309,835.36. Following the sale, the director now directly owns 44,166 shares in the company, valued at approximately $2,286,032.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, November 13th. The shares were sold at an average price of $55.39, for a total transaction of $166,170.00. Following the completion of the sale, the director now owns 7,127 shares in the company, valued at $394,764.53. The disclosure for this sale can be found here. Insiders sold a total of 133,885 shares of company stock worth $7,002,841 over the last quarter. Company insiders own 2.13% of the company’s stock.
A number of hedge funds have recently modified their holdings of IONS. Majedie Asset Management Ltd increased its stake in shares of Ionis Pharmaceuticals by 8.8% during the 4th quarter. Majedie Asset Management Ltd now owns 80,696 shares of the company’s stock worth $4,059,000 after purchasing an additional 6,500 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Ionis Pharmaceuticals by 3.2% during the 4th quarter. American Century Companies Inc. now owns 1,181,109 shares of the company’s stock worth $59,410,000 after purchasing an additional 36,583 shares during the last quarter. North Star Asset Management Inc. acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth about $765,000. IFG Advisory LLC acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth about $256,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Ionis Pharmaceuticals by 163.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,198 shares of the company’s stock worth $261,000 after purchasing an additional 3,223 shares during the last quarter. Hedge funds and other institutional investors own 91.44% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/02/06/0-08-eps-expected-for-ionis-pharmaceuticals-inc-ions-this-quarter.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.